Overactive JAK pathway signaling is a key driver of PV2,3
Two Janus-associated kinases (JAK) play a role in signaling2,3:


JAK, Janus-associated kinase; PV, polycythemia vera; STAT, signal transducer and activator of transcription.
Two Janus-associated kinases (JAK) play a role in signaling2,3:
JAK, Janus-associated kinase; PV, polycythemia vera; STAT, signal transducer and activator of transcription.
Mechanism of Action of Jakafi® (ruxolitinib)
Hematology specialist Dr Harry Erba reviews the mechanism of action of Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, highlighting how Jakafi works to inhibit overactive JAK pathway signaling. Dr Erba also discusses safety data from the RESPONSE† trial, which compared Jakafi to best available therapy for patients with polycythemia vera who were either intolerant of or had an inadequate response to hydroxyurea.
†RESPONSE, Randomized study of Efficacy and Safety in POlycythemia vera with JAK iNhibitor ruxolitinib verSus bEst available care
References
Indications and Usage
Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.